RSV Immunization Campaign for Infants & High-Risk Children – Glen Gower

Summary of Ontario’s ⁣Respiratory Virus Prevention Program (VRS) for Infants & pregnant People

This document outlines Ontario’s program to protect infants from Respiratory Syncytial⁣ Virus (RSV) using two main methods:‍ Beyfortus^MD (monoclonal antibody) and Abrysvo^MC (prenatal vaccine).

Key Points:

* Beyfortus^MD (for Infants): The preferred method for infant protection.
* Eligibility:

* Infants born on or‍ after April 1st, 2025, and under 8 months‍ old during the RSV season (Nov-April).
⁤ ‍ * Infants under 8 months born before the ‍RSV season – consult a healthcare provider. SPO (Specialized Pediatric Outreach) offers it to those without a regular provider via the ⁢”Children Above All” clinic.
* Children 24 months⁤ or less with high-risk conditions (see list below).
‍* High-Risk Conditions for Beyfortus^MD:

* Chronic lung disease of prematurity (including bronchopulmonary dysplasia)
* Significant congenital heart disease
‍ * Severe immunodeficiency
⁤ * Down⁢ Syndrome (Trisomy 21)
* Cystic fibrosis with ⁣respiratory involvement/growth retardation
* Neuromuscular disease
‍ * Serious congenital respiratory tract anomalies
* Administration: Pediatricians, primary care providers, hospitals, and ambulatory clinics. SPO ‍does not administer Beyfortus^MD to high-risk children.

* ⁢ Abrysvo^MC (for Pregnant People):

* Eligibility: Pregnant people between 32-36 weeks gestation, expecting to deliver during the RSV season (Nov-April), after consulting their healthcare provider.
* Administration: ⁢ Not⁢ offered in SPO⁣ clinics.
* ⁢ Recommendation: Monoclonal antibody administration to the infant is the recommended approach. using both products isn’t expected to provide extra benefit.
* Timing: Both programs begin October 1st. the RSV season is generally November to ⁣April.

In essence,⁢ the program prioritizes giving infants direct protection via Beyfortus^MD, while ⁤offering a prenatal option (Abrysvo^MC) for pregnant people.